arrow
M

Michael C. Wu

swog
H指数:54
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

可手术切除的增生性黑色素瘤的新辅助PD-1阻滞: SWOG S1512 2期试验的队列A

2026-01-290
OAAI
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial

不可切除的增生性黑色素瘤的Anti-PD-1治疗: SWOG S1512 2期试验

2025-08-140
PRE
Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder
2024-10-010
PRE
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
2024-05-164
OAAI
Biopsy analysis of trial S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with anti-PD-1 refractory melanoma
2024-03-220
PRE
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
2023-08-1743
OA
S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma
2023-04-141
PRE
Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607
2023-04-042
PRE